Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine Plus Temozolomide in Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367Phase 1Recruiting
- Sponsor
- Orbus Therapeutics
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eflornithine in glioblastoma (GBM) and astrocytoma (3 arms), sponsored by Orbus Therapeutics. Primary endpoints: Assessment of Dose Limiting Toxicities at 8 weeks, Incidence of TEAEs All Grades and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
eflornithine
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT05879367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879367.